Trial reportAmerican journal of respiratory and critical care medicine2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One
Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIIMulticenter Study
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05576324 (Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor on Numerical Distribution in Peripheral Mononuclear Immune Cells Derived From Patients With Cystic Fibrosis), which is not on this map. Cited by 155 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
155citing papers in PubMed, 5 pooled it
28.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor on Numerical Distribution in Peripheral Mononuclear Immune Cells Derived From Patients With Cystic Fibrosis
Who cites it
155 citing papers in PubMed, 5 syntheses or guidelines pooled it, 272 citations in OpenAlex.
- A systematic review and meta-analysis of the treatment modalities available for children afflicted from cystic fibrosis.BMC pediatrics · 2025Pooled it
- Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations: A Systematic Review.Clinical pharmacokinetics · 2025Pooled it
- Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2025Pooled it
- Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Efficacy and Safety of Triple Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Patients With Cystic Fibrosis: A Meta-Analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2022Pooled it
- Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study.Annals of the American Thoracic Society · 2026Trial
- Impact of 2 years of treatment with elexacaftor/tezacaftor/ivacaftor on longitudinal changes in structural lung disease in people with cystic fibrosis: results from the RECOVER trial.Annals of the American Thoracic Society · 2026Trial
- Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous forThe European respiratory journal · 2025Trial
- Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.The Lancet. Respiratory medicine · 2025Trial
- Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous forAnnals of the American Thoracic Society · 2023Trial
- Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous forAmerican journal of respiratory and critical care medicine · 2022Trial
- Physiologically Based Pharmacokinetic Modeling of Elexacaftor-Tezacaftor-Ivacaftor in Adults and Pediatric People with Cystic Fibrosis: Exploring Brain Exposure and Neuropsychiatric Adverse Events.Clinical pharmacokinetics · 2026Article
- Anti-inflammatory and phosphorylation effects of CFTR modulator triple therapy in cystic fibrosis.iScience · 2026Article
- Thermophysiological and perceptual responses to exercise heat stress in people with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor.Experimental physiology · 2026Article
- DNA sequencing for microbial surveillance in cystic fibrosis airways: advances, challenges, and clinical translation.Clinical microbiology reviews · 2026Review
- Elastic Fibers in the Pathogenesis of Cystic Fibrosis: Mechanisms, Consequences, and Therapeutic Implications.Life (Basel, Switzerland) · 2026Review
- Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis.British journal of clinical pharmacology · 2026Observational
- SOLAR: a noninterventional study of outcomes over the long term of people with cystic fibrosis (CF) aged ≥6 years treated with elexacaftor/tezacaftor/ivacaftor using data from the French CF Registry.ERJ open research · 2026Article
- Patient-Reported Health-Related Quality of Life in Romanian Patients with Cystic Fibrosis in the Era of Highly Effective CFTR Modulator Therapy: A National Cross-Sectional Mixed-Methods Survey.Journal of clinical medicine · 2026Article
- Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis.Pediatric pulmonology · 2026Article
95 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
22 authors at 13 institutions in 6 countries.
Edith T ZemanickDepartment of Pediatrics, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, Colorado.
Jennifer L Taylor-CousarDepartment of Medicine and.
Jane DaviesNational Heart and Lung Institute, Imperial College London, National Institute for Health Research Imperial Biomedical Research Centre and Royal Brompton and Harefield National Health Service Foundation Trust, London, United Kingdom.
Ronald L GibsonUniversity of Washington/Seattle Children's Hospital, Seattle, Washington.
Marcus A MallDepartment of Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-4057-2199
Edward F McKoneSt. Vincent's University Hospital and University College, Dublin, Ireland.
Paul McNallyChildren's Health Ireland and Royal College of Surgeons in Ireland University of Medicine and Health Sciences, Dublin, Ireland.ORCID 0000-0001-7102-1712
Bonnie W RamseyUniversity of Washington/Seattle Children's Hospital, Seattle, Washington.
Jonathan H RaymentBritish Columbia Children's Hospital, Vancouver, British Columbia, Canada.
Steven M RoweUniversity of Alabama at Birmingham, Birmingham, Alabama.ORCID 0000-0001-9045-0133
Elizabeth TullisSt. Michael's Hospital, Toronto, Ontario, Canada.
Neil AhluwaliaVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Chenghao ChuVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Thang HoVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Samuel M MoskowitzVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Sabrina NoelVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Simon TianVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
David WaltzVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Tanya G WeinstockVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Fengjuan XuanVertex Pharmaceuticals Incorporated, Boston, Massachusetts.
Claire E WainwrightUniversity of Queensland, Brisbane, Queensland, Australia.
Susanna A McColleyAnn and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; and.
Vertex Pharmaceuticals (United States) · USSeattle Children's Hospital · USBC Children's Hospital · CAChildren's Hospital Colorado · USGerman Center for Lung Research · DENational Health Service · GBNational Jewish Health · USNorthwestern University · USRoyal College of Surgeons in Ireland · IESt. Michael's Hospital · CAThe University of Queensland · AUUniversity College Dublin · IEUniversity of Alabama at Birmingham · US
Funding
UAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Brian R. Davis · 2007 to 2026
$23.0MNIDDK NIH HHS P30 DK072482
Abstract
PubMed holds no abstract for this paper.
Indexed as
AllelesChildChloride Channel AgonistsCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsFemaleGenetic VariationGenotypeHumansIndolesMalePyrazolesQuinolonesChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsIndolesPyrazolesQuinoloneschildcystic fibrosiselexacaftorivacaftortezacaftor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT05576324ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.